BioSpace News Archive

Ajinomoto Bio-Pharma Services (“Aji Bio-Pharma”), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce it has entered into a manufacturing agreement with Humanigen, Inc., for the fill finish supply of lenzilumab, currently being studied in a Phase III clinical trial in adult, hospita

Pear Therapeutics, Inc. today announced that Corey McCann, M.D., Ph.D., President and CEO, will present at the Jefferies Virtual Global Healthcare Conference on Wednesday, June 3 at 4:30 p.m. Eastern Time. About Pear Therapeutics Pear Therapeutics is the leader in prescription digital therapeutics, or PDTs. Pear aims to redefine medicine by discovering, developing, and delivering clinically valida

- First presentation of the SELECT-CHOICE study evaluating efficacy and safety of RINVOQ™ (upadacitinib) compared to abatacept in patients with moderate to severe active rheumatoid arthritis - New long-term efficacy and safety data of up to 84 weeks in rheumatoid arthritis patients receiving RINVOQ alone and in combination with methotrexate to be presented - Three new analyses to be presented evaluating the safety profile of RINVOQ in patients with rheumatoid arthritis

Artesunate for Injection 110 mg, powder and solvent for solution is approved by FDA for initial treatment of severe malaria in adult and pediatric patients. Artesunate for Injection is in a group of drugs known as “artemisinin derivatives” and is on the World Health Organization Model List of Essential Medicines .

The IN SITE™ Metastasis Kit provides key features of the cancer microenvironment to increase predictiveness and improve decision making in development of anti-cancer drugs [27-May-2020] NEW YORK , May 27, 2020 /PRNewswire/ -- Xylyx Bio , a leader in predictive disease models, today announced the release of its IN SITE™ Metastasis Kit, a highly physiologic system that

- First Quarter 2020 Revenues Increase 38% to $8.4 Million - - WatchPAT™ Revenues Increase 41% to $8.2 Million - - Company to Host Conference Call Today at 8:00 am ET, 3:00 pm IT - CAESAREA, Israel, May 27, 2020 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq and TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices and solutions to aid in the diagnosis of respiratory sleep disorders, today report

ENZYMLOGIC S.L. (Enzymlogic) today announced that the European Patent Office has issued EU patent EP3350596B1 covering a novel method for determining kinetic profiles in drug discovery. This proprietary technology is applicable to the early stages of drug discovery, enabling key insight into important factors that influence efficacy, safety and new therapeutic opportunity. Enzymlogic has exclusive rights to the patented technology which underpins its KINETICfinder platform.

Innovative agreement provides flexible model to address Genmab’s development and manufacturing needs as programs advance in development Rentschler Biopharma’s U.S. site expansion progressing on track with plans to significantly increase square footage and number of employees

GlaxoSmithKline (GSK) plc today announced new data from the DREAMM (DRiving Excellence in Approaches to Multiple Myeloma) clinical programme, which further highlight the potential of the investigational anti-BCMA (antibody drug conjugate against B-cell maturation antigen) agent belantamab mafodotin for relapsed/refractory multiple myeloma both as a monotherapy and in combination

Circle Pharma, Inc., a macrocycle drug discovery and development company focused on intractable cancer targets, has appointed William G. Kaelin Jr. MD as Chair of its Scientific Advisory Board and Science Advisor to its Board of Directors. Dr. Kaelin is a Howard Hughes Medical Institute Investigator and a professor of medicine at Dana Farber Cancer Institute and Harvard Medical School. He was awarded the